PDF herunterladen
CC BY-NC-ND 4.0 · J Lab Physicians 2023; 15(03): 377-382
DOI: 10.1055/s-0043-1761454
Original Article

Effect of COVID-19 Vaccination on the Levels of SARS-CoV-2 Neutralizing Antibodies in COVID-19 Naive, Hybrid, and Breakthrough SARS-CoV-2 Recovered Indian Individuals

Gujjarlapudi Deepika 
1   Department of Biochemistry, AIG Hospitals, Hyderabad, Telangana, India
,
Singamsetty Adarsh 
2   Department of Critical Care Medicine, AIG Hospitals, Hyderabad, Telangana, India
,
Yelamanchili Sadhana
3   Department of Microbiology, AIG Hospitals, Hyderabad, Telangana, India
,
Mahavadi Srihitha 
1   Department of Biochemistry, AIG Hospitals, Hyderabad, Telangana, India
,
Namburu Veeraiah
1   Department of Biochemistry, AIG Hospitals, Hyderabad, Telangana, India
,
Duvvur Nageshwar Reddy 
4   Department of Gastroenterology, AIG Hospitals, Hyderabad, Telangana, India
› Institutsangaben
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Introduction Vaccination has shown to be protective against severe coronavirus disease 2019 by various studies. However, the vaccine efficacy was demonstrated to be less against the emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Both vaccine- and infection-induced immunity against SARS-CoV-2 may prevent reinfection and severity. Our study aims to assess and compare the humoral response in heterogeneous population based on infection and vaccination status along with hybrid immunity.

Methods A retrospective, observational study of 2,545 adults was conducted. The study groups comprised of group I (n = 309) naive with a single dose of vaccination, group II (n = 357) infected and unvaccinated, group III (n = 590) completely vaccinated with two doses of vaccine, group IV (n = 70) booster dose, group V (n = 602) with hybrid immunity (pre-vaccination infection), and group VI (n = 617) with breakthrough infection (post-vaccination infection). Data pertaining to demographic details, clinical presentations, reverse transcription-polymerase chain reaction, anti-SARS-CoV-2 total antibodies immunoglobulin G (IgG), neutralizing antibodies by anti SARS-CoV-2 sVNT (surrogate virus neutralization test), S1/S2IgG, S-RBD (receptor-binding domain), and ChAdOx1-nCov-19 (Covishield) vaccination were retrieved from electronic health records.

Results The mean levels of neutralizing antibodies of group V were S1/S2, RBD (10.5/14.3 times), and sVNT (84.44%) and group VI had S1/S2, RBD (11.4/11.8 times), and sVNT (78.07%) when compared to group III. We also observed a statistically significant higher immune response in group V and VI than group I and II. A higher percentage (18.2%) of group II individuals had severe disease when compared to group V and VI (6.5/10.8%).

Conclusion A single dose of ChAdOx1 vaccine gives robust antibody responses in previously infected individuals and may confer long-term hybrid immunity following booster vaccination.

Keywords

COVID-19 vaccine - neutralizing antibodies and sVNT - SARS-CoV-2 - spike and RBD antibodies


Publikationsverlauf

Artikel online veröffentlicht:
06. Februar 2023

© 2023. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Voysey M, Clemens SAC, Madhi SA. et al; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397 (10269): 99-111
    CrossrefPubMedGoogle Scholar
  • 2 Moore JP, Offit PA. SARS-CoV-2 vaccines and the growing threat of viral variants. JAMA 2021; 325 (09) 821-822
    CrossrefPubMedGoogle Scholar
  • 3 Rinott E, Youngster I, Lewis YE. Reduction in COVID-19 patients requiring mechanical ventilation following implementation of a national COVID-19 vaccination program—Israel, December 2020–February 2021. MMWR Morb Mortal Wkly Rep 2021; 70 (09) 326-328
    CrossrefPubMedGoogle Scholar
  • 4 Rubin R. COVID-19 vaccines vs variants—determining how much immunity is enough. JAMA 2021; 325 (13) 1241-1243
    CrossrefPubMedGoogle Scholar
  • 5 Gilbert PB, Montefiori DC, McDermott AB. et al; Immune Assays Team§, Moderna, Inc. Team§, Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team§, United States Government (USG)/CoVPN Biostatistics Team§. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 2022; 375 (6576): 43-50
    CrossrefPubMedGoogle Scholar
  • 6 What You Need to Know About Variants. CDC Updates February 25, 2022
    PubMed
  • 7 Feng S, Phillips DJ, White T. et al; Oxford COVID Vaccine Trial Group. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med 2021; 27 (11) 2032-2040
    CrossrefPubMedGoogle Scholar
  • 8 Bergwerk M, Gonen T, Lustig Y. et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med 2021; 385 (16) 1474-1484
    CrossrefPubMedGoogle Scholar
  • 9 Kwok KO, Lai F, Wei WI, Wong SYS, Tang JWT. Herd immunity - estimating the level required to halt the COVID-19 epidemics in affected countries. J Infect 2020; 80 (06) e32-e33
    CrossrefPubMedGoogle Scholar
  • 10 WHO, Coronavirus disease (COVID-19)/COVID-19 vaccines https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines
  • 11 Levin EG, Lustig Y, Cohen C. et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med 2021; 385 (24) e84
    CrossrefPubMedGoogle Scholar
  • 12 World Health Organization. Clinical Management of COVID-19: Interim Guidance. Geneva, Switzerland: World Health Organization; 2020: 13-15
    Google Scholar
  • 13 Bates TA, McBride SK, Leier HC. et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Sci Immunol 2022; 7 (68) eabn8014
    CrossrefPubMedGoogle Scholar
  • 14 Krammer F, Srivastava K, Alshammary H. et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med 2021; 384 (14) 1372-1374
    CrossrefPubMedGoogle Scholar
  • 15 Naranbhai V, Garcia-Beltran WF, Chang CC. et al. Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2. S COVID-19 vaccines. J Infect Dis 2022; 225 (07) 1141-1150
    CrossrefPubMedGoogle Scholar
  • 16 Sasikala M, Shashidhar J, Deepika G. et al. Immunological memory and neutralizing activity to a single dose of COVID-19 vaccine in previously infected individuals. Int J Infect Dis 2021; 108: 183-186
    CrossrefPubMedGoogle Scholar
  • 17 Crotty S. Hybrid immunity. Science 2021; 372: 1392-1393
    CrossrefGoogle Scholar
  • 18 Rydyznski Moderbacher C, Ramirez SI, Dan JM. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 2020; 183 (04) 996-1012.e19
    CrossrefPubMedGoogle Scholar
  • 19 Jeewandara C, Kamaladasa A, Pushpakumara PD. et al. Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers. Nat Commun 2021; 12 (01) 4617
    CrossrefPubMedGoogle Scholar